KR20110044836A - 알파바이러스 레플리카제를 코딩하는 발현 벡터 및 면역 보조제로서 이의 용도 - Google Patents

알파바이러스 레플리카제를 코딩하는 발현 벡터 및 면역 보조제로서 이의 용도 Download PDF

Info

Publication number
KR20110044836A
KR20110044836A KR1020107029034A KR20107029034A KR20110044836A KR 20110044836 A KR20110044836 A KR 20110044836A KR 1020107029034 A KR1020107029034 A KR 1020107029034A KR 20107029034 A KR20107029034 A KR 20107029034A KR 20110044836 A KR20110044836 A KR 20110044836A
Authority
KR
South Korea
Prior art keywords
ala
leu
val
thr
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107029034A
Other languages
English (en)
Korean (ko)
Inventor
카자 키이버
레인 시쿠트
우르베 투츠
타모 묄더
안드레스 맨니크
마르트 우스타브
카트린 칼드마
Original Assignee
핏 바이오테크 오와이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 핏 바이오테크 오와이 filed Critical 핏 바이오테크 오와이
Publication of KR20110044836A publication Critical patent/KR20110044836A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107029034A 2008-05-23 2009-05-22 알파바이러스 레플리카제를 코딩하는 발현 벡터 및 면역 보조제로서 이의 용도 Ceased KR20110044836A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7189808P 2008-05-23 2008-05-23
US61/071,898 2008-05-23
PCT/EP2009/056240 WO2009141434A1 (en) 2008-05-23 2009-05-22 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant

Publications (1)

Publication Number Publication Date
KR20110044836A true KR20110044836A (ko) 2011-05-02

Family

ID=40910781

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107029034A Ceased KR20110044836A (ko) 2008-05-23 2009-05-22 알파바이러스 레플리카제를 코딩하는 발현 벡터 및 면역 보조제로서 이의 용도

Country Status (15)

Country Link
US (1) US9474800B2 (enExample)
EP (1) EP2296702A1 (enExample)
JP (1) JP5663474B2 (enExample)
KR (1) KR20110044836A (enExample)
CN (1) CN102083463B (enExample)
AU (1) AU2009248735B2 (enExample)
BR (1) BRPI0913045A2 (enExample)
CA (1) CA2724570A1 (enExample)
IL (1) IL209077A0 (enExample)
MX (1) MX2010012587A (enExample)
NZ (1) NZ589495A (enExample)
RU (1) RU2010152562A (enExample)
SG (1) SG191600A1 (enExample)
WO (1) WO2009141434A1 (enExample)
ZA (1) ZA201007880B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240049429A (ko) 2022-10-08 2024-04-16 최주언 황금비율 계량컵

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220119D0 (en) * 2012-11-08 2012-12-26 Univ Cork Vector
CN111304201B (zh) * 2020-02-21 2022-10-21 华南农业大学 一种降低乙型脑炎脑病毒感染的siRNA及其应用
AU2021233816A1 (en) 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods
BR112023002642A2 (pt) 2020-08-14 2023-04-04 Arcturus Therapeutics Inc Método para liofilizar nanopartículas lipídicas
CN113846113B (zh) * 2021-09-09 2022-09-13 臻赫医药(杭州)有限公司 一种有限自我复制mRNA分子系统、制备方法及应用
WO2023133509A2 (en) * 2022-01-08 2023-07-13 Carogen Corporation Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763584A (en) * 1992-05-18 1998-06-09 Genentech, Inc. Receptor activation with hepatocyte growth factor agonists
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
JP2002521461A (ja) * 1998-07-29 2002-07-16 インビトロゲン・コーポレーション Ｒｎａウイルスを用いる組換えタンパク質の調節発現
EP1226238A2 (en) * 1999-10-27 2002-07-31 Cytos Biotechnology AG Method for creating divergent populations of nucleic acid molecules and proteins
US7592005B2 (en) * 2000-12-28 2009-09-22 Kirin Beer Kabushiki Kaisha Monoclonal antibody
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
AU2003266301A1 (en) * 2002-08-22 2004-03-11 Cytos Biotechnology Ag Inducible alphaviral/orip based gene expression system
ES2222095B1 (es) * 2003-07-02 2005-11-16 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones.
WO2006085983A2 (en) * 2004-07-09 2006-08-17 University Of North Carolina At Chapel Hill Viral adjuvants
WO2008085557A2 (en) * 2006-09-12 2008-07-17 Alphavax, Inc. Alphavirus replicon particles encoding il- 12 as immunological adjuvants
HRP20100638T2 (hr) * 2006-11-28 2011-03-31 Proyecto De Biomedicina Cima Viralni vektori i njihova uporaba
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240049429A (ko) 2022-10-08 2024-04-16 최주언 황금비율 계량컵

Also Published As

Publication number Publication date
AU2009248735A1 (en) 2009-11-26
JP2011523642A (ja) 2011-08-18
CN102083463A (zh) 2011-06-01
RU2010152562A (ru) 2012-06-27
IL209077A0 (en) 2011-01-31
CN102083463B (zh) 2017-04-05
BRPI0913045A2 (pt) 2017-05-23
WO2009141434A1 (en) 2009-11-26
JP5663474B2 (ja) 2015-02-04
EP2296702A1 (en) 2011-03-23
MX2010012587A (es) 2011-05-25
SG191600A1 (en) 2013-07-31
CA2724570A1 (en) 2009-11-26
AU2009248735B2 (en) 2015-08-20
US20110171255A1 (en) 2011-07-14
WO2009141434A4 (en) 2010-01-14
NZ589495A (en) 2012-06-29
ZA201007880B (en) 2012-02-29
US9474800B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
EP3104878B1 (en) Immunotherapy of cancer through combination of local and systemic immune stimulation
AU2019202515B2 (en) Vaccine composition
AU2009264206B2 (en) Attenuated pestivirus
KR20110044836A (ko) 알파바이러스 레플리카제를 코딩하는 발현 벡터 및 면역 보조제로서 이의 용도
CN104271745A (zh) 用于治疗巨细胞病毒的组合物和方法
EA012037B1 (ru) Поливалентные вакцины, содержащие рекомбинантные вирусные векторы
US11352416B2 (en) Mosaic chimeric viral vaccine particle
US7417136B1 (en) Nucleic acid vaccines for prevention of flavivirus infection
JP2023520603A (ja) 免疫応答を引き起こすワクチン、アジュバント、及び方法
CN115335390A (zh) 基于SARS-CoV-2的S蛋白的疫苗和组合物
AU2013262426B2 (en) Cellular vaccine and method of inducing an immune response in a subject
KR20220086521A (ko) 신규 코로나바이러스 예방 및 치료용 백신 조성물
JP2024540505A (ja) ユニバーサルサルベコウイルスワクチン
KR20210122196A (ko) 신규 코로나바이러스 예방 및 치료용 백신 조성물
KR20220040423A (ko) 재조합 단백질을 포함하는 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
KR20230096564A (ko) A형 간염 바이러스 항원 단백질 및 이를 포함하는 백신 조성물
Hajam POTENTIATION OF IMMUNE RESPONSE AGAINST FOOT-AND-MOUTH DISEASE VIRUS USING TLR AGONISTS
Thompson Venezuelan equine encephalitis virus replicon particles: Mucosal vaccine vectors and biological adjuvants

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140520

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150914

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160328

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150914

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I